e-Therapeutics plc is a drug discovery and development company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and minimal side effects..
    The Company applies its novel, systematic approach in three areas of activity:
• Discovery of new de-risked drugs;
• Discovering novel uses for existing drugs; and
• Analysis of the interactions between different drugs.
    Amongst e-Therapeutics’ pipeline of compounds in development are an oral asthma treatment in Phase II clinical trials, a novel-mechanism antidepressant, also in Phase II clinical trials, novel antibiotics that have been shown to kill the “superbug” MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time.
    e-Therapeutics also provides evaluation services to investors, pharmaceutical and biotechnology companies, analysing drug candidates to determine their indication, efficacy and tolerance properties.